| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
N-Benzyloxycarbonylglycine does not have a biological target in the traditional sense. It is a chemical reagent used for peptide synthesis. The benzyloxycarbonyl (Cbz) group serves as a protecting group for the amino group of glycine, preventing unwanted side reactions during peptide bond formation. The Cbz group can be removed by hydrogenation or acid treatment. The compound is a building block for peptide and peptidomimetic synthesis.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are considered good synergistic dietary ingredients [1].
N-Benzyloxycarbonylglycine does not exhibit pharmacological activity. Its utility is in peptide synthesis and organic chemistry. It is used as a protected amino acid building block for the synthesis of peptides and peptidomimetics. The compound is a common reagent in chemical research. Detailed chemical properties are available in the primary literature. |
| ln Vivo |
In vivo data are not applicable for N-Benzyloxycarbonylglycine, as the compound is a chemical reagent rather than a therapeutic agent. It is not used in animal studies as a drug. Its applications are limited to chemical synthesis and research.
|
| Enzyme Assay |
In vitro, N-Benzyloxycarbonylglycine is used as a reagent in peptide synthesis. Standard peptide coupling protocols involve activation of the carboxylic acid group with coupling reagents (e.g., HATU, HBTU, or EDC) in the presence of a base (e.g., DIPEA or TEA). The reaction is carried out in anhydrous organic solvents (e.g., DMF or DCM) at room temperature for 2-24 hours. The Cbz protecting group is stable under these conditions. Deprotection can be achieved by hydrogenation with Pd/C or by treatment with HBr in acetic acid. The product is purified by column chromatography or recrystallization.
|
| Cell Assay |
Cell-based studies are not applicable for N-Benzyloxycarbonylglycine, as the compound is a chemical reagent rather than a therapeutic agent. It is not tested on cells for biological activity. Its applications are limited to chemical synthesis and research.
|
| Animal Protocol |
Animal studies are not applicable for N-Benzyloxycarbonylglycine, as the compound is a chemical reagent rather than a therapeutic agent. It is not used in animal studies as a drug. Its applications are limited to chemical synthesis and research.
|
| ADME/Pharmacokinetics |
N-Benzyloxycarbonylglycine (Z-Gly-OH, MW 209.20, C₁₀H₁₁NO₄) is a protected amino acid derivative. The compound is a white crystalline solid. It is soluble in organic solvents such as DMF, DCM, and methanol. Detailed physicochemical properties are available in chemical reference databases. The compound is for research and chemical synthesis purposes.
|
| Toxicity/Toxicokinetics |
N-Benzyloxycarbonylglycine is a chemical reagent and should be handled with standard laboratory safety precautions. It may cause irritation upon contact. Toxicity data are limited. The compound is for research use only and not intended for human therapeutic applications. Standard safety precautions for chemical handling apply.
|
| References | |
| Additional Infomation |
N-Benzyloxycarbonylglycine is a derivative of glycine with a benzyloxycarbonyl protecting group attached to its nitrogen atom. It is the conjugate acid of N-benzyloxycarbonylglycine ester. It has been reported that common bean (Phaseolus vulgaris) contains N-benzyloxycarbonylglycine, and relevant data are available for reference.
N-Benzyloxycarbonylglycine (Z-Gly-OH) is a research-grade protected amino acid for peptide synthesis. Its primary applications include peptide synthesis, organic chemistry, and chemical research. The compound is not a drug and has no clinical applications. It is commercially available from various chemical suppliers for research purposes only. Its use involves Cbz protection of the glycine amino group. |
| Molecular Formula |
C10H11NO4
|
|---|---|
| Molecular Weight |
209.201
|
| Exact Mass |
209.068
|
| CAS # |
1138-80-3
|
| PubChem CID |
14349
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
424.0±38.0 °C at 760 mmHg
|
| Melting Point |
118-122 °C(lit.)
|
| Flash Point |
210.2±26.8 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.554
|
| LogP |
1.37
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
15
|
| Complexity |
224
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C(N([H])C([H])([H])C(=O)O[H])=O)C([H])([H])C1C([H])=C([H])C([H])=C([H])C=1[H]
|
| InChi Key |
CJUMAFVKTCBCJK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H11NO4/c12-9(13)6-11-10(14)15-7-8-4-2-1-3-5-8/h1-5H,6-7H2,(H,11,14)(H,12,13)
|
| Chemical Name |
2-(phenylmethoxycarbonylamino)acetic acid
|
| Synonyms |
N-Carbobenzoxyglycine; Carbobenzoxyglycine; N-Benzyloxycarbonylglycine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~478.01 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.7801 mL | 23.9006 mL | 47.8011 mL | |
| 5 mM | 0.9560 mL | 4.7801 mL | 9.5602 mL | |
| 10 mM | 0.4780 mL | 2.3901 mL | 4.7801 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
